Ocular Therapeutix Reports Topline Phase 1 Data For AXPAXLI In Diabetic Retinopathy; AXPAXLI Was Generally Well Tolerated With No Inflammation Observed

Author: Benzinga Newsdesk | April 18, 2024 07:03am

Ocular plans to present the study results at an upcoming meeting. AXPAXLI was generally well tolerated with no inflammation observed including no incidence of iritis, vitritis or vasculitis. 6 of 13 (46.2%) patients in the AXPAXLI group experienced a 1 or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks, with 2 of the 6 having a 2-step improvement. "It is promising that the efficacy signals seen to date in this Phase 1 study consistently favor AXPAXLI. These data demonstrated DRSS improvements and durability for up to 40 weeks," said Dilsher Dhoot, MD.

Posted In: OCUL